These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 15860416)

  • 1. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
    Ranke MB
    Trends Endocrinol Metab; 2005; 16(4):190-7. PubMed ID: 15860416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic applications of the insulin-like growth factors.
    Savage MO; Camacho-Hübner C; Dunger DB
    Growth Horm IGF Res; 2004 Aug; 14(4):301-8. PubMed ID: 15231299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mecasermin (recombinant human insulin-like growth factor I).
    Rosenbloom AL
    Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with insulin-like growth factor I (IGF-I) treatment of growth hormone insensitivity syndrome (GHIS).
    Ranke MB; Wollmann HA; Savage MO
    J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():259-66. PubMed ID: 10698590
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes].
    Kato M
    Hokkaido Igaku Zasshi; 1998 Nov; 73(6):613-25. PubMed ID: 10036618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults.
    Yuen KC; Dunger DB
    Diabetes Obes Metab; 2007 Jan; 9(1):11-22. PubMed ID: 17199714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
    Dunger DB; Acerini CL
    Diabet Med; 1997 Sep; 14(9):723-31. PubMed ID: 9300221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
    Richmond EJ; Rogol AD
    Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone-resistant syndromes: long-term follow-up.
    Chernausek SD
    Endocr Dev; 2009; 14():135-42. PubMed ID: 19293580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults.
    Yuen KC; Dunger DB
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S55-61. PubMed ID: 16624605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant IGF-I therapy in insulin-dependent diabetes mellitus.
    Savage MO; Dunger DB
    Diabetes Metab; 1996 Jul; 22(4):257-60. PubMed ID: 8767172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.
    Nakae J; Kato M; Murashita M; Shinohara N; Tajima T; Fujieda K
    J Clin Endocrinol Metab; 1998 Feb; 83(2):542-9. PubMed ID: 9467572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of insulin-like growth factor-I in the control of glucose homeostasis.
    Clemmons DR
    Curr Opin Pharmacol; 2006 Dec; 6(6):620-5. PubMed ID: 17030015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations.
    Clark RG
    Horm Res; 2004; 62 Suppl 1():93-100. PubMed ID: 15761240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I.
    Scheiwiller E; Guler HP; Merryweather J; Scandella C; Maerki W; Zapf J; Froesch ER
    Nature; 1986 Sep 11-17; 323(6084):169-71. PubMed ID: 3528867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor 1 resistance in chronic renal failure.
    Fouque D
    Miner Electrolyte Metab; 1996; 22(1-3):133-7. PubMed ID: 8676805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.